Maple Leaf Green World (OTCQB:MGWFF,NEO:MGW) CEO Raymond Lai believes there are vast opportunities for cannabis companies tied to the growth of the North American markets.

In the interview below, Lai discusses the company’s facilities in BC, Nevada and California, the first of which will be completed within this year. Using its experience in eco-agriculture and greenhouse management, the company’s management team plans to position Maple Leaf Green World as a key cultivator for the medicinal and recreational cannabis markets.


Below is a transcript of our interview with Maple Leaf Green World CEO Raymond Lai. It has been edited for clarity and brevity.

Investing News Network: Please give our investor audience an overview of Maple Leaf.

Maple Leaf Green World CEO Raymond Lai: Maple Leaf Green World is a North American company concentrated on the cannabis sector. Our main focus is on providing cannabis-derived oil for medical use, as well as offering safe and high-quality cannabis for adult use. We have extensive greenhouse management experience, eco-agricultural knowledge and cultivation technology that can be applied directly to the production of high-quality cannabis products.

INN: How has Maple Leaf been developing its presence in the North American cannabis industry? Does the company have plans to expand to the international market?

RL: We currently have three projects which include Telkwa, BC; Henderson, Nevada; and Riverside County, California. Construction at our BC project will be completed before year end and our Nevada facility shortly thereafter. Upon completion, we will have over 47,000 square feet under roof. Immediately following, we plan to add 10 additional greenhouses to our property in California, giving us over 80,000 square feet under roof. Once these projects are completed, we will look to expand globally by exporting to countries where medical cannabis has been legalized.

INN: What is next for Maple Leaf and how does that fit into the company’s long-term plans?

RL: The completion of our projects in BC and Nevada will be a major milestone for us. This will enable us to begin cannabis cultivation and sales. Legalization of Canada’s recreational cannabis is set to occur in October of this year. This will not only open up a huge market for us, but it will also bring a lot of attention, legitimacy and advocacy to the medical benefits of cannabis. This is going to be a major industry and we have a lot of room to grow, both geographically and as a public company.

INN: Will the company’s primary focus be on medical or recreational cannabis?

RL: Maple Leaf’s primary focus is on medical cannabis to help patients achieve a quality of life. We are concentrated on producing high-quality cannabis and cannabis-derived oils and ultimately exporting these products to other countries that have legalized medical cannabis programs in place. However, with recreational cannabis soon to be legalized in Canada and already legalized in a number of states in the US, we also plan to launch recreational cannabis brands focused on providing a variety of products to market in both Canada and the US.

INN: How does Maple Leaf stand out within the medicinal cannabis industry?

RL: One of our advantages is our experience. We started off as an eco-agricultural company, allowing us to leverage over a decade of greenhouse management experience and cultivation technology that can be used directly for the production of high-quality cannabis products. We have also retained and are in the process of retaining a few key individuals with vast amounts of knowledge and experience in indoor cannabis cultivation. In addition, we believe we have a huge geographic advantage. Our land holdings in BC, Nevada and California have positioned the company strategically so that we can promptly respond to demand in both the medical and recreational cannabis markets in both Canada and the US.

INN: What other upcoming catalysts can investors expect for Maple Leaf?

RL: We will be making various announcements regarding the start of cultivation and production after our facilities are completed. This will include the sale of products, adding additional partners and entering into new markets to ultimately expand globally. We are really looking forward to seeing the continuous growth of our business and the rapid growth of the market.

CEO interviews are part of investor education campaigns for clients advertising on the Investing News Network. Important news is contextualized by CEOs, and the resulting interviews are disseminated to the Investing News Network audience because they have value to market watchers.

The Investing News Network interviews a CEO for an understanding of their perspective on the company, the investment potential of the company and market news related to the company. The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. 

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less